Inhibikase Therapeutics, Inc.

IKT

Held by 2 specialist biotech funds

Share on X

Fund Holdings

Perceptive Advisors Commodore Capital

AI Signal

AI analyst context — unlock full analysis

Catalysts

No catalysts tracked.

Position Details

Perceptive AdvisorsNEWFeb 17, 2026

Shares: 5,421,568Value: $11.1M

# Signal Note: Perceptive Advisors Initiates IKT Position Perceptive Advisors' $11.1M entry into Inhibikase signals confidence in IKT's lead asset, an inhibitor targeting Parkinson's disease and other synucleinopathies. The timing likely reflects upcoming clinical catalysts—IKT is advancing mid-stage programs with potential near-term data readouts that could validate target engagement or dose-response signals. Edelman's track record in early-stage clinical validation suggests conviction in IKT's mechanism, though the stock's modest valuation implies material clinical/regulatory risk remains priced in.

Commodore CapitalNEW

Know which insider moves are real

See who's buying with their own money vs. routine exercises
AI explains why each move matters right now

Start 7-Day Free Trial — $29/mo

Insider Signals

No insider signals tracked.

Also Held by These Funds

AMLX2 funds PALI2 funds RLAY2 funds ANRO2 funds CTMX2 funds COGT2 funds CTNM2 funds CNTA

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Track specialist biotech funds, insider signals, and AI analysis

Start 7-Day Free Trial

Or get the free weekly brief:

**Signal Note: Commodore Capital / Inhibikase Therapeutics (IKT)** Pellini's $11.1M initiation in IKT signals conviction in the company's lead program, IK-930, a selective inhibitor of Src family kinases in development for Parkinson's disease—a large, underserved neurodegenerative indication where disease-modifying therapies remain absent. The timing likely reflects anticipated clinical milestones, though near-term catalysts (Phase 2 data, trial progression) should be monitored closely to assess whether this represents foundational thesis or entry-point positioning.